Melanoma is a skin neoplasm that originates from malignant transformation of melanocytes.
It commonly occurs in the extremities of women and on trunk or head and neck in men.
Metastases are via lymphatic and hematogenous routes.
Use of oestrogen therapy alone appears to contribute to an increased risk of developing cutaneous melanoma, although the addition of progestins may counteract this unfavourable effect, a study has found.
Artificial intelligence (AI) methods appear to be effective for diagnosing melanoma, as the performance of traditional machine learning for the small dataset of melanoma dermoscopic images shows satisfactory results in a recent study.
A complete response to dabrafenib and trametinib treatment in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations leads to greater survival outcomes at 5 years, according to an analysis of data from the COMBI-d* and COMBI-v** trials.
Patients with advanced, unresectable melanoma may derive overall survival (OS) and progression-free survival (PFS) benefits when treated with a nivolumab plus ipilimumab combination or nivolumab alone, according to 4-year results of the phase III CheckMate 067* trial presented at ESMO 2018.
The FDA approval and subsequent use of checkpoint blockade immunotherapy (CBI) and BRAFV600 targeted therapy almost doubled the overall survival (OS) in patients with stage 4 melanoma with brain metastases (MBM), according to a recent US-based study.
Pembrolizumab delivered intravenously every 3 weeks for 1 year extended recurrence-free survival (RFS) in patients with resected stage III melanoma, according to results of the KEYNOTE-054/EORTC 1325-MG* trial.
Dermoscopy plus conventional and modified clinical ABCD criteria (amelanotic, bleeding bump, colour uniformity, de novo at any diameter) improves diagnosis of paediatric melanoma (PM), suggests a recent study. Dermoscopy helps in differentiating spitzoid from nonspitzoid melanomas.
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.